{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:38:32Z","timestamp":1790721512046,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003662","name":"Korea Evaluation Institute of Industrial Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2021-KH113823"],"award-info":[{"award-number":["RS-2021-KH113823"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119035","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T20:50:37Z","timestamp":1770411037000},"page":"119035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Evaluation of EB-203 as a potential treatment for non-proliferative diabetic retinopathy using a zebrafish model"],"prefix":"10.1016","volume":"196","author":[{"given":"Yujin","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-9757","authenticated-orcid":false,"given":"Jaewook","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119035_bib1","unstructured":"U.V. Shukla, K. Tripathy, Diabetic Retinopathy, StatPearls, Treasure Island (FL) ineligible companies. Disclosure: Koushik Tripathy declares no relevant financial relationships with ineligible companies., 2024."},{"issue":"4","key":"10.1016\/j.biopha.2026.119035_bib2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pathophys.2017.07.001","article-title":"Diabetic retinopathy: breaking the barrier","volume":"24","author":"Eshaq","year":"2017","journal-title":"Pathophysiology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s13167-023-00314-8","article-title":"Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation","volume":"14","author":"Kropp","year":"2023","journal-title":"Epma J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0161-6420(94)31354-6","article-title":"The relation of socioeconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision","volume":"101","author":"Klein","year":"1994","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.biopha.2026.119035_bib5","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00125-017-4333-0","article-title":"Retinal vascular geometry and 6 year incidence and progression of diabetic retinopathy","volume":"60","author":"Cheung","year":"2017","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/ijem.ijem_480_21","article-title":"Diabetic retinopathy: an overview of treatments","volume":"26","author":"Mounirou","year":"2022","journal-title":"Indian J. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2026.119035_bib7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4093\/dmj.2018.0182","article-title":"Pathophysiology of diabetic retinopathy: the old and the new","volume":"42","author":"Kusuhara","year":"2018","journal-title":"Diabetes Metab. J."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.18502\/jovr.v17i1.10175","article-title":"Update on management of non-proliferative diabetic retinopathy without diabetic macular Edema; is there a paradigm shift?","volume":"17","author":"Arabi","year":"2022","journal-title":"J. Ophthalmic Vis. Res"},{"issue":"10","key":"10.1016\/j.biopha.2026.119035_bib9","article-title":"Laser treatment modalities for diabetic retinopathy","volume":"14","author":"Pande","year":"2022","journal-title":"Cureus"},{"issue":"14","key":"10.1016\/j.biopha.2026.119035_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93751","article-title":"Diabetic retinopathy: current understanding, mechanisms, and treatment strategies","volume":"2","author":"Duh","year":"2017","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.biopha.2026.119035_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/02813432.2018.1487524","article-title":"Diabetic retinopathy -incidence and risk factors in a community setting- a longitudinal study","volume":"36","author":"Shani","year":"2018","journal-title":"Scand. J. Prim. Health Care"},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4239\/wjd.v6.i1.92","article-title":"Ocular complications of diabetes mellitus","volume":"6","author":"Sayin","year":"2015","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.biopha.2026.119035_bib13","article-title":"Determining risk factors that affect progression in patients with nonproliferative diabetic retinopathy","volume":"2021","author":"Chen","year":"2021","journal-title":"J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119035_bib14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.diabres.2014.09.018","article-title":"Risk factors for development and progression of nonproliferative retinopathy in normoalbuminuric patients with type 1 diabetes","volume":"106","author":"Bulum","year":"2014","journal-title":"Diabetes Res Clin. Pr."},{"issue":"9","key":"10.1016\/j.biopha.2026.119035_bib15","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(03)00475-5","article-title":"Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales","volume":"110","author":"Wilkinson","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.biopha.2026.119035_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","article-title":"Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss","volume":"2","author":"Lee","year":"2015","journal-title":"Eye Vis."},{"issue":"3","key":"10.1016\/j.biopha.2026.119035_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.pop.2015.05.005","article-title":"Diabetic retinopathy","volume":"42","author":"Hendrick","year":"2015","journal-title":"Prim. Care"},{"issue":"10","key":"10.1016\/j.biopha.2026.119035_bib18","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1167\/iovs.13-12654","article-title":"Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008-2011","volume":"54","author":"Jee","year":"2013","journal-title":"Investig. Ophth Vis. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119035_bib19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of Diabetic Retinopathy in the US in 2021","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.biopha.2026.119035_bib20","unstructured":"The Four Stages of Diabetic Retinopathy, The four stages of diabetic retinopathy, modernoptometry, 2019, pp. 21\u201324."},{"issue":"31","key":"10.1016\/j.biopha.2026.119035_bib21","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1093\/eurheartj\/eht149","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"34","author":"Paneni","year":"2013","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jcjd.2020.10.009","article-title":"Diabetic retinopathy: important biochemical alterations and the main treatment strategies","volume":"45","author":"ValdezGuerrero","year":"2021","journal-title":"Can. J. Diabetes"},{"issue":"3","key":"10.1016\/j.biopha.2026.119035_bib23","doi-asserted-by":"crossref","first-page":"H738","DOI":"10.1152\/ajpheart.00005.2016","article-title":"Neurovascular cross talk in diabetic retinopathy: pathophysiological roles and therapeutic implications","volume":"311","author":"Moran","year":"2016","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119035_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2026.119035_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1477-7525-6-95","article-title":"The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy","volume":"6","author":"Matza","year":"2008","journal-title":"Health Qual. Life Outcomes"},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061816","article-title":"Diabetic retinopathy: pathophysiology and treatments","volume":"19","author":"Wang","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfo.2023.08.004","article-title":"Proliferative diabetic retinopathy: role of bevacizumab in decreasing the occurrence of vitreous hemorrhage after panretinal photocoagulation","volume":"47","author":"Nehme","year":"2024","journal-title":"J. Fr. Ophtalmol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119035_bib28","article-title":"Update on the management of diabetic retinopathy: anti-VEGF agents for the prevention of complications and progression of nonproliferative and proliferative retinopathy","volume":"13","author":"Bahr","year":"2023","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2022-001190","article-title":"Simulation of long-term impact of intravitreal anti-VEGF therapy on patients with severe non-proliferative diabetic retinopathy","volume":"8","author":"Nguyen","year":"2023","journal-title":"BMJ Open Ophthalmol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119035_bib30","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41433-022-02269-y","article-title":"Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials","volume":"37","author":"Chaudhary","year":"2023","journal-title":"Eye (Lond. )"},{"issue":"4","key":"10.1016\/j.biopha.2026.119035_bib31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ecl.2013.08.001","article-title":"Diabetic retinopathy: current concepts and emerging therapy","volume":"42","author":"Rosberger","year":"2013","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.biopha.2026.119035_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/728325","article-title":"The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment","volume":"2012","author":"Tremolada","year":"2012","journal-title":"Exp. Diabetes Res"},{"issue":"9","key":"10.1016\/j.biopha.2026.119035_bib33","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.ophtha.2013.02.002","article-title":"Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema","volume":"120","author":"Stein","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ophtha.2014.08.048","article-title":"Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy","volume":"122","author":"Ip","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3892\/mmr.2014.2722","article-title":"Effects of topical chondrocyte-derived extracellular matrix treatment on corneal wound healing, following an alkali burn injury","volume":"11","author":"Yang","year":"2015","journal-title":"Mol. Med Rep."},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00417-014-2633-3","article-title":"Anti-neovascular effect of chondrocyte-derived extracellular matrix on corneal alkaline burns in rabbits","volume":"252","author":"Lee","year":"2014","journal-title":"Graefe's. Arch. Clin. Exp. Ophthalmol. = Albrecht Von. Graefes Arch. fur Klin. und Exp. Ophthalmol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119035_bib38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00417-014-2592-8","article-title":"Effect of porcine chondrocyte-derived extracellular matrix on the pterygium in mouse model","volume":"252","author":"Lee","year":"2014","journal-title":"Graefe's. Arch. Clin. Exp. Ophthalmol. = Albrecht Von. Graefes Arch. fur Klin. und Exp. Ophthalmol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119035_bib39","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1016\/j.biomaterials.2014.03.083","article-title":"Inhibition of blood vessel formation by a chondrocyte-derived extracellular matrix","volume":"35","author":"Choi","year":"2014","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib40","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1038\/s41598-017-07965-4","article-title":"Anti-inflammatory effect of hydroxyproline-GQDGLAGPK in desiccation stress-induced experimental dry eye mouse","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib41","doi-asserted-by":"crossref","first-page":"35946","DOI":"10.1038\/s41598-025-20272-7","article-title":"Screening and evaluation of therapeutic candidates with vascular protective effects in zebrafish models of diabetic retinopathy","volume":"15","author":"Lee","year":"2025","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2026.119035_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108771","article-title":"Zebrafish as an experimental model for human disease","volume":"24","author":"Tonon","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119035_bib43","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s12276-021-00571-5","article-title":"Zebrafish as an animal model for biomedical research","volume":"53","author":"Choi","year":"2021","journal-title":"Exp. Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119035_bib44","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1007\/s11033-023-08263-1","article-title":"Zebrafish, a biological model for pharmaceutical research for the management of anxiety","volume":"50","author":"Chahardehi","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib45","first-page":"147","article-title":"New photic stimulating system with white light-emitting diodes to elicit electroretinograms from zebrafish larvae, Documenta ophthalmologica","volume":"135","author":"Matsubara","year":"2017","journal-title":"Adv. Ophthalmol."},{"key":"10.1016\/j.biopha.2026.119035_bib46","unstructured":"How widely are zebrafish used in Europe?, 2020. \u3008https:\/\/www.eara.eu\/zebrafish-and-animal-research\u3009."},{"issue":"8","key":"10.1016\/j.biopha.2026.119035_bib47","doi-asserted-by":"crossref","DOI":"10.1098\/rsbl.2022.0541","article-title":"Flight for fish in drug discovery: a review of zebrafish-based screening of molecules","volume":"19","author":"Dash","year":"2023","journal-title":"Biol. Lett."},{"issue":"7","key":"10.1016\/j.biopha.2026.119035_bib48","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/bjp.2008.249","article-title":"Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery","volume":"154","author":"Barros","year":"2008","journal-title":"Br. J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1021\/acs.chemrestox.9b00335","article-title":"Use of zebrafish in drug discovery toxicology","volume":"33","author":"Cassar","year":"2020","journal-title":"Chem. Res Toxicol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/ijp.IJP_482_19","article-title":"Zebrafish: an emerging whole-organism screening tool in safety pharmacology","volume":"52","author":"Nikam","year":"2020","journal-title":"Indian J. Pharm."},{"key":"10.1016\/j.biopha.2026.119035_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111201","article-title":"Development of a zebrafish screening model for diabetic retinopathy induced by hyperglycemia: reproducibility verification in animal model","volume":"135","author":"Lee","year":"2021","journal-title":"Biomed. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2026.119035_bib52","article-title":"Non-proliferative diabetic retinopathy is characterized by nonuniform alterations of peripapillary capillary networks","volume":"61","author":"An","year":"2020","journal-title":"Invest Ophth Vis. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119035_bib53","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2337\/dc16-2641","article-title":"Diabetic retinopathy: a position statement by the American diabetes association","volume":"40","author":"Solomon","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib54","first-page":"425","article-title":"Current and future approaches in the prevention and treatment of diabetic retinopathy","volume":"2","author":"Chang","year":"2008","journal-title":"Clin. Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.sjopt.2011.01.009","article-title":"Diabetic retinopathy - an update","volume":"25","author":"Alghadyan","year":"2011","journal-title":"Saudi J. Ophthalmol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib56","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2174\/1573399813666170915133253","article-title":"Diabetic retinopathy: recent updates on different biomarkers and some therapeutic agents","volume":"14","author":"Khan","year":"2018","journal-title":"Curr. Diabetes Rev."},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib57","first-page":"44","article-title":"Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy","volume":"53","author":"Koleva-Georgieva","year":"2011","journal-title":"Folia Med (Plovdiv. )"},{"issue":"12","key":"10.1016\/j.biopha.2026.119035_bib58","doi-asserted-by":"crossref","first-page":"5594","DOI":"10.1167\/iovs.17-21973","article-title":"Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy","volume":"58","author":"Boss","year":"2017","journal-title":"Investig. Ophth Vis. Sci."},{"key":"10.1016\/j.biopha.2026.119035_bib59","unstructured":"N. Mahabadi, Y.Al Khalili, Neuroanatomy, Retina, StatPearls, Treasure Island (FL) ineligible companies. Disclosure: Yasir Al Khalili declares no relevant financial relationships with ineligible companies., 2024."},{"issue":"7","key":"10.1016\/j.biopha.2026.119035_bib60","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/dvdy.24375","article-title":"Muller glial cell-dependent regeneration of the neural retina: An overview across vertebrate model systems","volume":"245","author":"Hamon","year":"2016","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.biopha.2026.119035_bib61","doi-asserted-by":"crossref","first-page":"15296","DOI":"10.1038\/ncomms15296","article-title":"Plastic roles of pericytes in the blood-retinal barrier","volume":"8","author":"Park","year":"2017","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2026.119035_bib62","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4103\/1673-5374.133169","article-title":"The development of blood-retinal barrier during the interaction of astrocytes with vascular wall cells","volume":"9","author":"Yao","year":"2014","journal-title":"Neural Regen. Res"},{"key":"10.1016\/j.biopha.2026.119035_bib63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-60761-938-3_5","article-title":"The blood-retinal barrier: structure and functional significance","volume":"686","author":"Runkle","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119035_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105115","article-title":"Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy","volume":"161","author":"Rudraraju","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2026.119035_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bcp.2019.07.010","article-title":"Blood-retinal barrier protection against high glucose damage: the role of P2X7 receptor","volume":"168","author":"Platania","year":"2019","journal-title":"Biochem Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib66","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.exer.2009.07.017","article-title":"Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells","volume":"89","author":"Villarroel","year":"2009","journal-title":"Exp. Eye Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib67","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1575-0922(09)70552-2","article-title":"High glucose concentration leads to differential expression of tight junction proteins in human retinal pigment epithelial cells","volume":"56","author":"Villarroel","year":"2009","journal-title":"Endocrinol. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib68","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00125-006-0485-z","article-title":"Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases","volume":"50","author":"Hawkins","year":"2007","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib69","first-page":"101","article-title":"Translation: DNA to mRNA to protein","volume":"1","author":"Clancy","year":"2008","journal-title":"Nat. Educ."},{"issue":"11","key":"10.1016\/j.biopha.2026.119035_bib70","first-page":"951","article-title":"RNA sequencing and analysis","author":"Kukurba","year":"2015","journal-title":"Cold Spring Harb. Protoc. 2015"},{"issue":"5","key":"10.1016\/j.biopha.2026.119035_bib71","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.ajpath.2021.01.016","article-title":"Sustained inhibition of NF-kappaB activity mitigates retinal vasculopathy in diabetes","volume":"191","author":"Homme","year":"2021","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119035_bib72","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/diabetes.51.7.2241","article-title":"Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes","volume":"51","author":"Romeo","year":"2002","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.biopha.2026.119035_bib73","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1167\/iovs.06-1473","article-title":"Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway","volume":"48","author":"Nagai","year":"2007","journal-title":"Invest Ophth Vis. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib74","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db09-0801","article-title":"Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands","volume":"59","author":"Yao","year":"2010","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.biopha.2026.119035_bib75","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-017-0135-z","article-title":"Cellular death, reactive oxygen species (ROS) and diabetic complications","volume":"9","author":"Volpe","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2026.119035_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1037186","article-title":"Advanced glycation end products in diabetic retinopathy and phytochemical therapy","volume":"9","author":"Kang","year":"2022","journal-title":"Front Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12933-023-01965-7","article-title":"The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction","volume":"22","author":"An","year":"2023","journal-title":"Cardiovasc Diabetol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119035_bib78","doi-asserted-by":"crossref","DOI":"10.2174\/1573399817666210118145550","article-title":"The role of alpha-lipoic acid supplementation in the prevention of diabetes complications: a comprehensive review of clinical trials","volume":"17","author":"Jeffrey","year":"2021","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.biopha.2026.119035_bib79","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-kappaB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2026.119035_bib80","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/582060","article-title":"Diabetic retinopathy: vascular and inflammatory disease","volume":"2015","author":"Semeraro","year":"2015","journal-title":"J. Diabetes Res"},{"issue":"4","key":"10.1016\/j.biopha.2026.119035_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19040942","article-title":"Role of inflammation in diabetic retinopathy","volume":"19","author":"Rubsam","year":"2018","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119035_bib82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13578-022-00839-x","article-title":"A novel and atypical NF-KB pro-inflammatory program regulated by a CamKII-proteasome axis is involved in the early activation of Muller glia by high glucose","volume":"12","author":"Sbardella","year":"2022","journal-title":"Cell Biosci."},{"key":"10.1016\/j.biopha.2026.119035_bib83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuroscience.2018.02.035","article-title":"Autophagy- and MMP-2\/9-mediated Reduction and Redistribution of ZO-1 Contribute to Hyperglycemia-increased Blood-Brain Barrier Permeability During Early Reperfusion in Stroke","volume":"377","author":"Zhang","year":"2018","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.biopha.2026.119035_bib84","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1210\/jc.2008-2534","article-title":"Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications","volume":"94","author":"Goldberg","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2026.119035_bib85","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/935301","article-title":"Vitreous mediators in retinal hypoxic diseases","volume":"2013","author":"dell'Omo","year":"2013","journal-title":"Mediat. Inflamm."},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib86","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1517\/13543784.2012.681043","article-title":"Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9","volume":"21","author":"Kowluru","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2026.119035_bib87","first-page":"804","article-title":"Matrix metalloproteinase-9 and vascular endothelial growth factor expression change in experimental retinal neovascularization","volume":"9","author":"Di","year":"2016","journal-title":"Int J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119035_bib88","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/labinvest.3700251","article-title":"Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier","volume":"85","author":"Giebel","year":"2005","journal-title":"Lab Invest"},{"issue":"7","key":"10.1016\/j.biopha.2026.119035_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159720","article-title":"Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the aqueous humor of diabetic macular edema patients","volume":"11","author":"Kwon","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2026.119035_bib90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15407\/fz62.05.037","article-title":"Role of matrix metalloproteinase 9 and its tissue inhibitor 1 in development and prognosis of diabetic retinopathy","volume":"62","author":"Ziablitsev","year":"2016","journal-title":"Fiziol. Zh."},{"key":"10.1016\/j.biopha.2026.119035_bib91","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3389\/fphar.2017.00798","article-title":"NF-kappabeta: a potential target in the management of vascular complications of diabetes","volume":"8","author":"Suryavanshi","year":"2017","journal-title":"Front Pharm."},{"key":"10.1016\/j.biopha.2026.119035_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117146","article-title":"HMGB1 upregulates NF-kB by inhibiting IKB-alpha and associates with diabetic retinopathy","volume":"241","author":"Liang","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119035_bib93","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.vph.2018.04.005","article-title":"Chebulagic acid Chebulinic acid and Gallic acid, the active principles of Triphala, inhibit TNFalpha induced pro-angiogenic and pro-inflammatory activities in retinal capillary endothelial cells by inhibiting p38, ERK and NFkB phosphorylation","volume":"108","author":"Shanmuganathan","year":"2018","journal-title":"Vasc. Pharm."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:50:35Z","timestamp":1781880635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226000673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":93,"alternative-id":["S0753332226000673"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119035","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of EB-203 as a potential treatment for non-proliferative diabetic retinopathy using a zebrafish model","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119035"}}